The Decentralised Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The COVID-19 pandemic necessitated unprecedented adaptation on the part of life sciences organisations worldwide, for better or for worse, on a scale that has not been witnessed before in the contemporary industry. In response to the pandemic, biopharmaceutical companies and contract research organisations (CROs) have implemented decentralised or digital clinical trials (DCTs) as a means of minimising contact, enhancing the patient experience, and maintaining the progress of studies. The advantages of utilising virtual methods in the context of digital clinical trials are evident and have proven to be advantageous for life science entities. The clinical trial landscape has undergone a transformation with advancements in operational aspects such as patient engagement and site experience, cost reduction, and improved data integration. This shift has resulted in the acceptance of DCTs as a viable approach for conducting clinical studies.
Nevertheless, there are still obstacles to be overcome. The integration of conventional clinical trial obstacles with those arising from the shift towards digital solutions and decentralised designs characterises this novel clinical trial paradigm. The responsibility lies with biopharmaceutical companies and Contract Research Organizations (CROs) to comprehend and identify the challenges that arise during the implementation of a decentralised clinical trial. The achievement of academic success is contingent upon the assessment and integration of user-friendly remedies that can be expeditiously executed and simplified without imposing undue burden on healthcare professionals and recipients, all while upholding security and regulatory protocols.
The COVID-19 pandemic necessitated unprecedented adaptation on the part of life sciences organisations worldwide, for better or for worse, on a scale that has not been witnessed before in the contemporary industry. In response to the pandemic, biopharmaceutical companies and contract research organisations (CROs) have implemented decentralised or digital clinical trials (DCTs) as a means of minimising contact, enhancing the patient experience, and maintaining the progress of studies. The advantages of utilising virtual methods in the context of digital clinical trials are evident and have proven to be advantageous for life science entities. The clinical trial landscape has undergone a transformation with advancements in operational aspects such as patient engagement and site experience, cost reduction, and improved data integration. This shift has resulted in the acceptance of DCTs as a viable approach for conducting clinical studies.
Nevertheless, there are still obstacles to be overcome. The integration of conventional clinical trial obstacles with those arising from the shift towards digital solutions and decentralised designs characterises this novel clinical trial paradigm. The responsibility lies with biopharmaceutical companies and Contract Research Organizations (CROs) to comprehend and identify the challenges that arise during the implementation of a decentralised clinical trial. The achievement of academic success is contingent upon the assessment and integration of user-friendly remedies that can be expeditiously executed and simplified without imposing undue burden on healthcare professionals and recipients, all while upholding security and regulatory protocols.
What Questions Should You Ask before Buying a Market Research Report?
- How is the decentralised clinical trials market evolving?
- What is driving and restraining the decentralised clinical trials market?
- How will each decentralised clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
- How will the market shares for each decentralised clinical trials submarket develop from 2023 to 2033?
- What will be the main driver for the overall market from 2023 to 2033?
- Will leading decentralised clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
- Who are the leading players and what are their prospects over the forecast period?
- What are the decentralised clinical trials projects for these leading companies?
- How will the industry evolve during the period between 2023 and 2033? What are the implications of
- Is there a greater need for product commercialisation to further scale the decentralised clinical trials market?
- Where is the decentralised clinical trials market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the decentralised clinical trials market today, and over the next 10 years:
- Our 278-page report provides 120 tables and 158 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
Segments Covered in the Report
Indication
- Oncology
- Cardiovascular
- Immunology
- Respiratory
- Others
Study Design
- Interventional
- Observational
- Expanded Access
End-users
- Pharmaceutical and Biopharmaceutical Companies
- CROs
- Others
Component
- Mobile Healthcare
- Telemedicine
- Wearable Devices
- Web-based Technology
- Others
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Singapore
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies and the potential for market growth
- CASTOR EDC
- Clinical ink
- CLOUDZBY, INC.
- Dassault Systèmes (Medidata Solutions, Inc.)
- ERGOMED PLC
- FLORENCE HEALTHCARE INC.
- ICON PLC
- IQVIA Holdings, Inc.
- Labcorp Drug Development
- Medable, Inc.
- Medrio Inc.
- Oracle Corporation
- Parexel International Corporation
- PPD (Thermo Fisher Scientific Inc.)
- Syneos Health
How will the Decentralised Clinical Trials Market, 2023 to 2033 report help you?
In summary, this 270+ page report provides you with the following knowledge:- Revenue forecasts to 2033 for Decentralised Clinical Trials Market, 2023 to 2033 Market, with forecasts for indication, study design, end-users, and component, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 23 key national markets - See forecasts for the Decentralised Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 15 of the major companies involved in the Decentralised Clinical Trials Market, 2023 to 2033.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Decentralised Clinical Trials Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Decentralised Clinical Trials Market Analysis by Indication
5 Decentralised Clinical Trials Market Analysis by Study Design
6 Decentralised Clinical Trials Market Analysis by End-users
7 Decentralised Clinical Trials Market Analysis by Component
8 Decentralised Clinical Trials Market Analysis by Region
9 North America Decentralised Clinical Trials Market Analysis
10 Europe Decentralised Clinical Trials Market Analysis
11 Asia Pacific Decentralised Clinical Trials Market Analysis
12 Latin America Decentralised Clinical Trials Market Analysis
13 MEA Decentralised Clinical Trials Market Analysis
14 Company Profiles
15 Conclusion and Recommendations
Companies Mentioned
- CASTOR EDC
- Clinical ink
- CLOUDZBY, INC.
- Dassault Systèmes (Medidata Solutions, Inc.)
- ERGOMED PLC
- FLORENCE HEALTHCARE INC.
- ICON PLC
- IQVIA Holdings, Inc.
- Labcorp Drug Development
- Medable, Inc.
- Medrio Inc.
- Oracle Corporation
- Parexel International Corporation
- PPD (Thermo Fisher Scientific Inc.)
- Syneos Health
- ADAMAS Consulting Group Limited
- Aetion
- AliveCor
- Allucent
- Aural Analytics
- Biobeat
- BioNTech
- Blue Spark Technologies
- Boco Digital Media, LLC
- Boehringer Ingelheim
- Circuit Clinical
- Clalit Health Services
- Click Therapeutics
- ClinChoice
- Clinical Research Malaysia
- Cognizant
- Compliance Quest
- ConcertAI, LLC
- Cryoport, Inc.
- CVS Health
- Datavant
- Digital Artefacts
- Equicare
- Every Cure
- Fosun Pharma USA Inc.
- Genexine
- GI Partners
- GlobalCare
- Glooko
- GSK
- Haystack Health
- HealthCore
- HealthVerity, Inc.
- HMD Clinical
- Illingworth Research Group
- Indie Health
- Janssen
- LEO Pharma
- Lightship
- Lupus Therapeutics
- Matrix Medical Network
- Microsoft
- Mural Health
- Odaseva
- Pfizer
- PHARMASEAL International Ltd.
- PHASTAR
- PRA Health Sciences, Inc.
- Q² Solutions
- RxDataScience
- Science 37
- Seqster
- Servier
- StudyKIK
- Tasso
- Tech Mahindra
- Trialbee
- TriNetX
- Vault Health, Inc.
- Veeva System
- Withings Health Solutions
- American Telemedicine Association (ATA)
- Association for Clinical Data Management (ACDM)
- Association of Clinical Research Organizations (ACRO)
- Center for Biologics Evaluation and Research (CBER)
- Center for Devices and Radiological Health (CDRH)
- Center of Excellence in Immunology (CEI)
- Centers for Disease Control and Prevention (CDC)
- European Medicines Agency (EMA)
- Food and Drug Administration (FDA)
- Global Genes RARE Corporate Alliance
- Indian Council of Medical Research (ICMR)
- Institute for Healthcare Improvement (IHI)
- International Agency for Research on Cancer (IARC)
- Medicines and Healthcare Products Regulatory Agency (MHRA)
- Ministry of Health, Labour & Welfare (MHLW)
- National Cancer Institute (NCI)
- National Cancer Institute's Center for Cancer Research (CCR)
- National Center for Biotechnology Information (NCBI)
- National Development and Reform Commission (NDRC)
- National Institutes of Health (NIH)
- United Nations (UN)
- World Health Organization (WHO)